Works matching DE "THERAPEUTIC use of monoclonal antibodies"

Results: 5000

Multi-center phase II study of nab-paclitaxel plus camrelizumab versus nab-paclitaxel alone as second-line treatment for advanced gastric cancer.

Published in:

Oncologist, 2025, v. 30, n. 7, p. 1, doi. 10.1093/oncolo/oyaf189

By:

Sun, Li;
Gong, Zhimin;
Wang, Lei;
Kuang, Li;
Huang, Qiao;
Pei, Bo;
Yuan, Xianglin;
Qiu, Hong

Publication type:

Article

New tool in the toolbox: patient selection for zolbetuximab in advanced treatment-naïve gastric/gastroesophageal junction adenocarcinoma.

Published in:

Oncologist, 2025, v. 30, n. 7, p. 1, doi. 10.1093/oncolo/oyaf185

By:

Grewal, Udhayvir S;
Brown, Timothy J

Publication type:

Article

Real-world outcomes of first-line treatment with HLX02 versus reference trastuzumab plus pertuzumab in HER2-positive metastatic breast cancer.

Published in:

Oncologist, 2025, v. 30, n. 7, p. 1, doi. 10.1093/oncolo/oyaf183

By:

Yan, Ying;
Zhang, Ruyan;
Li, Yanling;
Di, Lijun;
Gui, Xinyu;
Jiang, Hanfang;
Liang, Xu;
Shao, Bin;
Song, Guohong;
Li, Huiping

Publication type:

Article

Long-term safety analysis of pooled data for tislelizumab as monotherapy or in combination with chemotherapy in patients with advanced cancers.

Published in:

Oncologist, 2025, v. 30, n. 7, p. 1, doi. 10.1093/oncolo/oyaf177

By:

Zhou, Caicun;
Huang, Rose;
Yuan, Yuan;
Schnell, Patrick;
Wu, John;
Kadva, Alysha;
Mehmeti, Jola;
Ajani, Jaffer

Publication type:

Article

First-line treatment with HDACis plus tislelizumab combined with chemotherapy in advanced NSCLC: a single-arm phase II study.

Published in:

Oncologist, 2025, v. 30, n. 7, p. 1, doi. 10.1093/oncolo/oyaf155

By:

Wang, Lijie;
Gao, Ming;
Wang, Ting;
Cui, Pengfei;
Chen, Guangying;
Han, Xiao;
Ma, Zhiqiang;
Yang, Wenyu;
Jing, Fangfang;
Ma, Junxun;
Zhang, Fan;
Tao, Haitao;
Hu, Yi

Publication type:

Article

First-in-human phase I open-label study of the LAG-3 antagonist antibody INCAGN02385 in patients with select advanced or metastatic solid tumors.

Published in:

Oncologist, 2025, v. 30, n. 7, p. 1, doi. 10.1093/oncolo/oyaf136

By:

Powderly, John D;
Gutierrez, Martin E;
Balmanoukian, Ani S;
Hoyle, Paul E;
Dong, Zhiwan;
Cheng, Lulu;
Chen, Xuejun;
Janik, John E;
Bourayou, Nawel;
Hamid, Omid

Publication type:

Article

Safety and quality of life with maintenance olaparib plus bevacizumab in older patients with ovarian cancer: subgroup analysis of PAOLA‑1/ENGOT-ov25.

Published in:

Oncologist, 2025, v. 30, n. 7, p. 1, doi. 10.1093/oncolo/oyae322

By:

Montégut, Coline;
Falandry, Claire;
Cinieri, Saverio;
Cropet, Claire;
Montane, Laure;
Rousseau, Frédérique;
Joly, Florence;
Moubarak, Malak;
Mosconi, Anna M;
Guerra-Alía, Eva M;
Schauer, Christian;
Fujiwara, Hiroyuki;
Vergote, Ignace;
Parma, Gabriella;
Lindahl, Gabriel;
Anota, Amélie;
Canzler, Ulrich;
Marmé, Frederik;
Pujade-Lauraine, Eric;
Ray-Coquard, Isabelle

Publication type:

Article

Correction to: Efficacy and Safety of Camrelizumab, Apatinib, and Capecitabine Combination Therapy in Advanced Biliary Tract Cancer: A Single-arm Prospective Study.

Published in:: Oncologist, 2025, v. 30, n. 7, p. 1, doi. 10.1093/oncolo/oyae307
Publication type:: Article

Evaluation of a risk-sharing agreement for atezolizumab treatment in patients with non-small cell lung cancer: a strategy to improve access in low-income countries.

Published in:

Oncologist, 2025, v. 30, n. 7, p. 1, doi. 10.1093/oncolo/oyae272

By:

Arrieta, Oscar;
Ramos-Ramírez, Maritza;
Garcés-Flores, Homero;
Cabrera-Miranda, Luis A;
Gómez-García, Ana Pamela;
Soto-Molina, Herman;
Cardona, Andrés F;
Valencia-Velarde, Ángel;
Gálvez-Niño, Marco;
Guzmán-Vázquez, Silvia

Publication type:

Article

Recaticimab: First Approval.

Published in:

Drugs, 2025, v. 85, n. 8, p. 1067, doi. 10.1007/s40265-025-02199-5

By:

Lamb, Yvette N.

Publication type:

Article

Sipavibart: First Approval.

Published in:

Drugs, 2025, v. 85, n. 8, p. 1049, doi. 10.1007/s40265-025-02186-w

By:

Keam, Susan J.

Publication type:

Article

만성 비부비동염의 치료: 약물치료 및 새로운 치료법을 중심으로.

Published in:

Journal of the Korean Medical Association / Taehan Uisa Hyophoe Chi, 2025, v. 68, n. 7, p. 427, doi. 10.5124/jkma.25.0079

By:

Park, Sang Chul

Publication type:

Article

난치성 비부비동염의 치료.

Published in:

Journal of the Korean Medical Association / Taehan Uisa Hyophoe Chi, 2025, v. 68, n. 7, p. 436, doi. 10.5124/jkma.25.0077

By:

Cho, Jae Hoon

Publication type:

Article

Pretreatment with an anti-CGRP monoclonal antibody attenuates mild TBI-induced tactile hypersensitivity in mice.

Published in:

Journal of Headache & Pain, 2025, v. 26, n. 1, p. 1, doi. 10.1186/s10194-025-02108-x

By:

Wattiez, Anne-Sophie;
Kuburas, Adisa;
Castonguay, William C.;
Fejgin, Kim;
Klewe, Ib V.;
Russo, Andrew F.

Publication type:

Article

The need of preexposure prophylaxis against COVID-19 in immunocompromised patients– an assessment from Germany.

Published in:

Infection, 2025, v. 53, n. 4, p. 1541, doi. 10.1007/s15010-025-02540-w

By:

Gerstenberg, Jacob;
Lübbert, Christoph;
Widera, Marek;
Schleenvoigt, Benjamin T.

Publication type:

Article

A randomized, double blind, placebo-controlled pilot study to assess the efficacy of erenumab in individuals with temporomandibular disorder.

Published in:

Journal of Oral & Facial Pain & Headache, 2025, v. 39, n. 2, p. 75, doi. 10.22514/jofph.2025.027

By:

Avila, Harold C.;
Kroenke, Kurt;
Eckert, George J.;
Gossweiler, Ana G.;
Galvez, Lorena del Carmen;
Zero, Domenick T.

Publication type:

Article

Dose finding in early-phase human immunodeficiency virus type 1 prevention monoclonal antibody clinical trials.

Published in:

Clinical Trials, 2025, v. 22, n. 4, p. 442, doi. 10.1177/17407745251347280

By:

Huang, Yunda;
Zhang, Bo;
Zhang, Lily;
Mayer, Bryan T;
Martin, Troy;
Hahn, William;
Hyrien, Ollivier;
Gelderblom, Huub C

Publication type:

Article

Calcitonin gene-related peptide monoclonal antibody treatment for new daily persistent headache.

Published in:

Journal of Headache & Pain, 2025, v. 26, n. 1, p. 1, doi. 10.1186/s10194-025-02111-2

By:

Cheema, Sanjay;
Rantell, Khadija Rerhou;
Pickering, Rachel;
Lagrata, Susie;
Kamourieh, Salwa;
Matharu, Manjit

Publication type:

Article

Population-Based Analysis of the Risk of Mycobacterial Infections Associated With Immune Checkpoint Inhibitors Open Access.

Published in:

Clinical Infectious Diseases, 2025, v. 81, n. 1, p. 176, doi. 10.1093/cid/ciae626

By:

Yan, Marie;
Hernandez, Alejandro;
Chan, Kelvin K;
Stanbrook, Matthew B;
Blanchette, Phillip S;
Johnston, James C;
Lee, Samantha M;
Macdonald, Liane;
Richard-Greenblatt, Melissa;
Marras, Theodore K;
Brode, Sarah K

Publication type:

Article

A Randomized, Placebo-Controlled Phase 2 Trial of CNTO 6785 in Chronic Obstructive Pulmonary Disease.

Published in:

COPD: Journal of Chronic Obstructive Pulmonary Disease, 2017, v. 14, n. 5, p. 476, doi. 10.1080/15412555.2017.1335697

By:

Eich, Andreas;
Urban, Veronika;
Jutel, Marek;
Vlcek, Jiri;
Shim, Jae Jeong;
Trofimov, Vasiliy I.;
Liam, Chong-Kin;
Kuo, Ping-Hung;
Hou, Yanyan;
Xiao, Jun;
Branigan, Patrick;
O'Brien, Christopher D.

Publication type:

Article

Effective treatments for respiratory syncytial virus infection in children remain elusive but prevention tools are now available.

Published in:

Drugs & Therapy Perspectives, 2025, v. 41, n. 5, p. 177, doi. 10.1007/s40267-025-01157-1

By:

Shirley, Matt

Publication type:

Article

Manage chronic hand eczema with conventional treatments, but emerging therapies show promise.

Published in:

Drugs & Therapy Perspectives, 2025, v. 41, n. 4, p. 146, doi. 10.1007/s40267-025-01155-3

By:

Zhuang-Yan, Amy

Publication type:

Article

Regulatory and clinical aspects in biosimilar medicines: comparability, extrapolation, interchangeability, and safety: Biosimilar medicines: evaluating comparability, extrapolation, interchangeability, and safety: M. C. Raposo et al.

Published in:

Drugs & Therapy Perspectives, 2025, v. 41, n. 3, p. 111, doi. 10.1007/s40267-025-01145-5

By:

Raposo, Miguel C.;
Feiteira, Cláudia;
Ribeiro, Maria H. L.

Publication type:

Article

Correction: Rozanolixizumab in generalized myasthenia gravis: a profile of its use.

Published in:

2024

By:

Hoy, Sheridan M.

Publication type:

Correction Notice

Mirikizumab in moderately to severely active ulcerative colitis: a profile of its use.

Published in:

Drugs & Therapy Perspectives, 2024, v. 40, n. 11, p. 433, doi. 10.1007/s40267-024-01114-4

By:

Fung, Simon;
Blair, Hannah A.

Publication type:

Article

Lecanemab in Alzheimer's disease: a profile of its use.

Published in:

Drugs & Therapy Perspectives, 2024, v. 40, n. 10, p. 393, doi. 10.1007/s40267-024-01108-2

By:

Blair, Hannah A.

Publication type:

Article

Adis summary of research: Omalizumab in severe asthma: effect on oral corticosteroid exposure and remodelling. A randomized open-label parallel study.

Published in:

Drugs & Therapy Perspectives, 2024, v. 40, n. 8, p. 291, doi. 10.1007/s40267-024-01083-8

By:

Syed, Yahiya Y.

Publication type:

Article

Rozanolixizumab in generalized myasthenia gravis: a profile of its use.

Published in:

Drugs & Therapy Perspectives, 2024, v. 40, n. 6, p. 203, doi. 10.1007/s40267-024-01077-6

By:

Hoy, Sheridan M.

Publication type:

Article

Aim to alleviate alopecia areata with newly available agents.

Published in:

Drugs & Therapy Perspectives, 2024, v. 40, n. 5, p. 181, doi. 10.1007/s40267-024-01069-6

By:

Fenton, Caroline;
Kang, Connie

Publication type:

Article

Mirvetuximab soravtansine in folate receptor alpha-positive, platinum-resistant ovarian cancers: a profile of its use.

Published in:

Drugs & Therapy Perspectives, 2024, v. 40, n. 2, p. 53, doi. 10.1007/s40267-024-01050-3

By:

Fung, Simon;
Syed, Yahiya Y.

Publication type:

Article

Correction to: Tezepelumab in severe asthma: a profile of its use.

Published in:

2024

By:

Syed, Yahiya Y.

Publication type:

Correction Notice

Nirsevimab in the prevention of respiratory syncytial virus lower respiratory tract disease: a profile of its use.

Published in:

Drugs & Therapy Perspectives, 2023, v. 39, n. 12, p. 413, doi. 10.1007/s40267-023-01039-4

By:

Shirley, Matt

Publication type:

Article

The PHASTER Study: Economic and Organizational Impact of Subcutaneous (SC) Pertuzumab and Trastuzumab Fixed-Dose Combination (PH FDC SC) for Treatment of HER2+ Breast Cancer Patients.

Published in:

Drugs & Therapy Perspectives, 2023, v. 39, n. 12, p. 432, doi. 10.1007/s40267-023-01038-5

By:

Munzone, Elisabetta;
Fabi, Alessandra;
Buono, Giuseppe;
Caputo, Roberta;
Montagna, Emilia;
Negri, Mara;
Nuzzo, Francesco;
Palazzo, Antonella;
Paris, Ida;
Conti, Luca;
Baggi, Anna;
Franzini, Jean Marie;
De Laurentiis, Michelino

Publication type:

Article

Spesolimab in generalised pustular psoriasis flares: a profile of its use.

Published in:

Drugs & Therapy Perspectives, 2023, v. 39, n. 12, p. 404, doi. 10.1007/s40267-023-01034-9

By:

Nie, Tina

Publication type:

Article

Tezepelumab in severe asthma: a profile of its use.

Published in:

Drugs & Therapy Perspectives, 2023, v. 39, n. 12, p. 393, doi. 10.1007/s40267-023-01033-w

By:

Syed, Yahiya Y.

Publication type:

Article

Ublituximab in relapsing forms of multiple sclerosis: a profile of its use.

Published in:

Drugs & Therapy Perspectives, 2023, v. 39, n. 11, p. 365, doi. 10.1007/s40267-023-01030-z

By:

Blair, Hannah A.

Publication type:

Article

Consider new therapies for the treatment and prevention of Clostridioides difficile infection.

Published in:

Drugs & Therapy Perspectives, 2023, v. 39, n. 7, p. 237, doi. 10.1007/s40267-023-01006-z

By:

Fenton, Caroline;
Kang, Connie

Publication type:

Article

Calcitonin gene-related peptide-targeted therapies are effective options for the prevention and treatment of migraine.

Published in:

Drugs & Therapy Perspectives, 2023, v. 39, n. 6, p. 195, doi. 10.1007/s40267-023-00995-1

By:

Nie, Tina

Publication type:

Article

Nivolumab/relatlimab in advanced melanoma: a profile of its use.

Published in:

Drugs & Therapy Perspectives, 2023, v. 39, n. 3, p. 89, doi. 10.1007/s40267-023-00980-8

By:

Lee, Arnold

Publication type:

Article

Aducanumab: a review of the first approved amyloid-targeting antibody for Alzheimer's disease.

Published in:

Drugs & Therapy Perspectives, 2022, v. 38, n. 10, p. 443, doi. 10.1007/s40267-022-00944-4

By:

Grover, Shubhima;
Jain, Seema

Publication type:

Article

Tisotumab vedotin-tftv in previously treated recurrent or metastatic cervical cancer: a profile of its use in the USA.

Published in:

Drugs & Therapy Perspectives, 2022, v. 38, n. 9, p. 382, doi. 10.1007/s40267-022-00939-1

By:

Kim, Esther S.;
Al-Salama, Zaina T.

Publication type:

Article

Anifrolumab in systemic lupus erythematosus: a profile of its use.

Published in:

Drugs & Therapy Perspectives, 2022, v. 38, n. 7, p. 293, doi. 10.1007/s40267-022-00925-7

By:

Lamb, Yvette N.

Publication type:

Article

Loncastuximab tesirine in relapsed or refractory diffuse large B-cell lymphoma: a profile of its use in the USA.

Published in:

Drugs & Therapy Perspectives, 2022, v. 38, n. 6, p. 261, doi. 10.1007/s40267-022-00922-w

By:

Markham, Anthony;
Al-Salama, Zaina T.

Publication type:

Article

Targeted therapy for metastatic colorectal cancer: what do we currently have in clinical practice?

Published in:

Drugs & Therapy Perspectives, 2022, v. 38, n. 5, p. 222, doi. 10.1007/s40267-022-00915-9

By:

Morgado, Sandra;
Silva, Mafalda;
Fonseca, Olímpia;
Roque, Fátima;
Morgado, Manuel

Publication type:

Article

Emerging small molecule antivirals may fit neatly into COVID-19 treatment.

Published in:

Drugs & Therapy Perspectives, 2022, v. 38, n. 3, p. 112, doi. 10.1007/s40267-022-00897-8

By:

Fenton, Caroline;
Keam, Susan J.

Publication type:

Article

Effectiveness of Combined I-chTNT and Radiofrequency Ablation Therapy in Treating Advanced Hepatocellular Carcinoma.

Published in:

Cell Biochemistry & Biophysics, 2015, v. 71, n. 2, p. 777, doi. 10.1007/s12013-014-0262-4

By:

Tu, Jianfei;
Ji, Jiansong;
Wu, Fazong;
Wang, Yonghui;
Zhang, Dengke;
Zhao, Zhongwei;
Ying, Xihui

Publication type:

Article

Expression of Sclerostin scFv and the Effect of Sclerostin scFv on Healing of Osteoporotic Femur Fracture in Rats.

Published in:

Cell Biochemistry & Biophysics, 2014, v. 69, n. 2, p. 229, doi. 10.1007/s12013-013-9787-1

By:

Yao, Qi;
Ni, Jie;
Hou, Yu;
Ding, Lixiang;
Zhang, Licheng;
Jiang, Hua

Publication type:

Article

The Effect of c-fos on Acute Myocardial Infarction and the Significance of Metoprolol Intervention in a Rat Model.

Published in:

Cell Biochemistry & Biophysics, 2013, v. 65, n. 2, p. 249, doi. 10.1007/s12013-012-9428-0

By:

Zhang, Song;
Zhang, Meiqi;
Goldstein, Steven;
Li, Yigang;
Ge, Junbo;
He, Ben;
Ruiz, George

Publication type:

Article

A case study of a patient with platelet transfusion refractoriness (PTR) combined with human leucocyte antigen (HLA) antibody positivity during hepatic arterial infusion chemotherapy in conjunction with the 'atezolizumab plus bevacizumab' regimen.

Published in:

Nursing in Critical Care, 2025, v. 30, n. 2, p. 1, doi. 10.1111/nicc.13118

By:

Xie, Yawen;
Huang, Yanxia;
Liu, Shuyue

Publication type:

Article

Clinical Profile of Statin Intolerance in the Phase 3 GAUSS-2 Study.

Published in:

Cardiovascular Drugs & Therapy, 2016, v. 30, n. 3, p. 297, doi. 10.1007/s10557-016-6655-4

By:

Cho, Leslie;
Rocco, Michael;
Colquhoun, David;
Sullivan, David;
Rosenson, Robert;
Dent, Ricardo;
Xue, Allen;
Scott, Rob;
Wasserman, Scott;
Stroes, Erik

Publication type:

Article